Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells

被引：25

作者：

Shida, D ^{[1
]}

Kitayama, J ^{[1
]}

Yamaguchi, H ^{[1
]}

Yamashita, H ^{[1
]}

Mori, K ^{[1
]}

Watanabe, T ^{[1
]}

Nagawa, H ^{[1
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Surg Oncol, Tokyo 1138655, Japan

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2005年 / 327卷 / 03期

关键词：

HER2/neu; lysophosphatidic acid; sphingosine; 1-phosphate; lysophospholipid; transactivation; receptor tyrosine kinase; gastric cancer;

D O I：

10.1016/j.bbrc.2004.12.088

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The ligand-less receptor HER2/neu (erbB-2) has been proposed as a prognostic marker of gastric cancer that correlates with poor clinical outcome, indicating that HER2 signals play an important role in gastric cancer progression. This study demonstrated that two Major natural lysophospholipids, lysophosphatidic acid (LPA) and sphingosine I-phosphate (SIP), induce rapid and transient phosphorylation of HER2 in two human gastric cancer cell lines, MKN28 and MKN74 cells. We also revealed that tyrosine phosphorylation of HER2 induced by both lysophospholipids was significantly attenuated by two inhibitors, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. This suggests that the pathway of HER2 transactivation induced by these lysophospholipids is dependent on the proteolytically released EGFR ligands. Our results indicate that LPA and SIP act upstream of HER2 in gastric cancer cells, and thus may act as potent stimulators of gastric cancer. (C) 2004 Elsevier Inc. All rights reserved.

引用

页码：907 / 914

页数：8

共 50 条

[21] RARE OCCURRENCE OF AMPLIFICATION OF HER-2 (ERBB-2/NEU) ONCOGENE IN OVARIAN-CANCER PATIENTS
IMYANITOV, EN
CHERNITSA, OI
SEROVA, OM
KNYAZEV, PG
EUROPEAN JOURNAL OF CANCER, 1992, 28A (6-7) : 1300 - 1300
[22] erbB-2 (HER-2) and breast cancer progression
Edgerton, SM
Moore, D
Merkel, D
Thor, AD
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2003, 11 (03) : 214 - 221
[23] The Tyrosine Kinase Receptor HER2 (erbB-2) From Oncogenesis to Adipogenesis
Vazquez-Martin, Alejandro
Jose Ortega-Delgado, Francisco
Manuel Fernandez-Real, Jose
Menendez, Javier A.
JOURNAL OF CELLULAR BIOCHEMISTRY, 2008, 105 (05) : 1147 - 1152
[24] Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells
Marcus, Elizabeth A.
Tokhtaeva, Elmira
Turdikulova, Shahlo
Capri, Joseph
Whitelegge, Julian P.
Scott, David R.
Sachs, George
Berditchevski, Fedor
Vagin, Olga
BIOCHEMICAL JOURNAL, 2016, 473 : 1703 - 1718
[25] Overexpression of HER2/neu in gastric cancer in South African patients
Swart, P. J.
Le Roux, G.
Myburg, M.
Beukes, C. A.
Goedhals, J.
HISTOPATHOLOGY, 2010, 57 : 93 - 94
[26] Overexpression and amplification of HER2/neu in human ovarian cancer
Lee, P
Sahin, A
Rosen, D
Liu, JS
MODERN PATHOLOGY, 2003, 16 (01) : 196A - 196A
[27] The role of linoleic acid metabolism in the proliferative response of cells overexpressing the erbB-2/HER2 oncogene
Glasgow, WC
Everhart, AL
EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY 3, 1997, 407 : 393 - 397
[28] NeuVax™ Anti-HER2/NEU/erbB-2 vaccine, Treatment of HER2-positive cancers
Davies, S.
DRUGS OF THE FUTURE, 2009, 34 (09) : 717 - 719
[29] Overexpression and amplification of HER2/neu in human ovarian cancer
Lee, P
Sahin, A
Rosen, D
Liu, JS
LABORATORY INVESTIGATION, 2003, 83 (01) : 196A - 196A
[30] Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
Xiu Li Zhang
Yun Sheng Yang
Dong Ping Xu
Jian Hui Qu
Ming Zhou Guo
Yan Gong
Jin Huang
World Journal of Surgery, 2009, 33 : 2112 - 2118

← 1 2 3 4 5 →